Results 181 to 190 of about 207,742 (277)

Predicting optimal impact interventions in the post‐HPV vaccination world

International Journal of Cancer, Volume 158, Issue 9, Page 2262-2271, 1 May 2026.
Abstract Prophylactic vaccination is a powerful tool that changes exposure to infections and associated morbidity of preventable diseases. We discuss the impact of pneumococci and human papillomavirus (HPV) vaccination on the population biology of the two micro‐organisms and related public health effects.
Matti Lehtinen, Marc Lipsitch, Ville N. Pimenoff, Karin Sundström, Johannes Berkhof, Iacopo Baussano, Simopekka Vänskä, Joakim Dillner   +7 more
wiley   +1 more source

Immunogenic insights and experimental validation of a multiepitope vaccine construct against <i>Streptococcus pneumoniae</i>. [PDF]

Front Immunol
Devarakonda Y, Reddy MVNJ, Binu A, Syal K.   +3 more
europepmc   +1 more source

Streptococcus pneumoniae [PDF]

, 2011
openaire   +1 more source

Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin, Paul Henderson, Richard Pollok, Natália Queiroz, Luca Fabris, Edoardo Vincenzo Savarino, Iago Rodríguez‐Lago, Brigida Barberio   +7 more
wiley   +1 more source

Purpura Fulminans and Septic Shock With Streptococcus pneumoniae Bacteraemia in a Patient With Unacknowledged Functional Hyposplenism. [PDF]

Cureus
Ramos Huamancondor C, Glorieux D.
europepmc   +1 more source

Serological immunity against vaccine‐preventable diseases in children with inflammatory bowel disease at diagnosis

JPGN Reports, Volume 7, Issue 2, Page 289-295, May 2026.
Abstract Objectives Patients with inflammatory bowel disease (IBD) are at increased risk of vaccine‐preventable diseases. However, vaccination coverage in this population is often suboptimal. This retrospective study assessed the vaccination status and vaccine serology of children diagnosed with IBD in a high‐income country with broad vaccine access ...
Clara Noble, Renato Gualtieri, Klara Posfay‐Barbe, Nathalie Rock, Geraldine Blanchard‐Rohner   +4 more
wiley   +1 more source

Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis

The Laryngoscope, Volume 136, Issue 5, Page 2048-2053, May 2026.
Elexacaftor–tezacaftor–ivacaftor (ETI) was associated with a significant decrease in the frequency and rate of endoscopic sinus surgeries in patients with cystic fibrosis. These findings suggest an improvement in CF‐related chronic rhinosinusitis outcomes following ETI and may influence future CF treatment decisions.
Amy Lin, Makanko Komara, Isaac Kistler, Zheng Hong Tan, Meredith Lind, Kavitha Kotha, Tendy Chiang   +6 more
wiley   +1 more source

Antimicrobial-resistant Streptococcus pneumoniae

Canadian Journal of Infectious Diseases, 1999
M Lovgren, JA Talbot
doaj   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

Metabolomic analysis of <i>Streptococcus pneumoniae</i>: uncovering key metabolic pathways. [PDF]

Front Microbiol
Jiang H, Zhao C, Feng L, Gao Y, Mi Z, He H.   +5 more
europepmc   +1 more source